Trial Profile
A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Jun 2014 New trial record